Literature DB >> 6952231

Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA.

J K Christman, M Gerber, P M Price, C Flordellis, J Edelman, G Acs.   

Abstract

3T3 cells containing hepatitis B virus DNA sequences can be efficiently selected by exposure to methotrexate after cotransfection with cloned viral DNA and DNA coding for a methotrexate-resistant dihydrofolate reductase. More than 75% of methotrexate-resistant cells isolated after cotransfection with a head-to-tail tandem of the hepatitis B virus genome synthesized viral surface antigen. The antigen was released into the culture medium in the form of 22-nm particles with buoyant density of 1.20 g/ml. No other virally coded proteins were detected in the cells or the culture medium. Application of selective pressure by increasing the concentration of methotrexate resulted in an amplification of viral DNA sequences and a concomitant increase in the rate of synthesis and release of hepatitis B surface antigen. The ability to produce large amounts of surface antigen appears to be a stable trait and has been maintained in these cultures through more than 30 passages.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6952231      PMCID: PMC346071          DOI: 10.1073/pnas.79.6.1815

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Ligation of EcoRI endonuclease-generated DNA fragments into linear and circular structures.

Authors:  A Dugaiczyk; H W Boyer; H M Goodman
Journal:  J Mol Biol       Date:  1975-07-25       Impact factor: 5.469

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

4.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

5.  Purification of naked intranuclear particles from human liver infected by hepatitis B virus.

Authors:  S Z Hirschman; M Gerber; E Garfinkel
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

6.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

7.  Australia antigen: large-scale purification from human serum and biochemical studies of its proteins.

Authors:  J L Gerin; P V Holland; R H Purcell
Journal:  J Virol       Date:  1971-05       Impact factor: 5.103

8.  A physical map of the DNA regions flanking the rabbit beta-globin gene.

Authors:  A J Jeffreys; R A Flavell
Journal:  Cell       Date:  1977-10       Impact factor: 41.582

9.  Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells.

Authors:  W F Flintoff; S V Davidson; L Siminovitch
Journal:  Somatic Cell Genet       Date:  1976-05

10.  Establishment of a continuously growing cell line from primary carcinoma of the liver.

Authors:  J J Alexander; E M Bey; E W Geddes; G Lecatsas
Journal:  S Afr Med J       Date:  1976-12-18
View more
  31 in total

1.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors:  S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells.

Authors:  R J Kaufman; L C Wasley; A J Spiliotes; S D Gossels; S A Latt; G R Larsen; R M Kay
Journal:  Mol Cell Biol       Date:  1985-07       Impact factor: 4.272

3.  Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.

Authors:  S Levine; D Hernandez; G Yamanaka; S Zhang; R Rose; S Weinheimer; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  Isolation and expression of an altered mouse dihydrofolate reductase cDNA.

Authors:  C C Simonsen; A D Levinson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

5.  Replicative intermediate of hepatitis B virus in transfected murine fibroblasts.

Authors:  A Z Zelent; M A Sells; M Shvartsman; P M Price; G Acs
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

Review 6.  Hepatitis B virus infection. Current concepts of chronicity and immunity.

Authors:  G N Vyas; H E Blum
Journal:  West J Med       Date:  1984-05

7.  Expression of hepatitis B antigens with a simian virus 40 vector.

Authors:  H Will; R Cattaneo; E Pfaff; C Kuhn; M Roggendorf; H Schaller
Journal:  J Virol       Date:  1984-05       Impact factor: 5.103

8.  Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.

Authors:  E Paoletti; B R Lipinskas; C Samsonoff; S Mercer; D Panicali
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Construction and use of a dominant, selectable marker: a Harvey sarcoma virus-dihydrofolate reductase chimera.

Authors:  M J Murray; R J Kaufman; S A Latt; R A Weinberg
Journal:  Mol Cell Biol       Date:  1983-01       Impact factor: 4.272

10.  Plasmid-directed synthesis of hepatitis B surface antigen in monkey cells.

Authors:  C W Crowley; C C Liu; A D Levinson
Journal:  Mol Cell Biol       Date:  1983-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.